New hope for tough lung cancers: experimental combo targets resistant tumors
NCT ID NCT07361484
First seen Jan 27, 2026 · Last updated May 20, 2026 · Updated 17 times
Summary
This study tests whether adding the experimental drug plinabulin to standard chemotherapy (docetaxel) helps people with advanced non-squamous non-small cell lung cancer live longer. It includes about 442 adults whose cancer has gotten worse after immunotherapy and platinum chemo, and who do not have certain genetic changes. Participants are randomly assigned to get either docetaxel plus plinabulin or docetaxel plus a placebo, and treatment continues until the cancer progresses or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.